Recommendations from the EGAPP Working Group: Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Genetics in Medicine

Volumn 15, Issue 7, 2013, Pages 517-527

  Calonge, Ned ^a   Fisher, Nancy L ^b   Berg, Alfred O ^c   Campos Outcalt, Doug ^d   Djulbegovic, Benjamin ^e   Ganiats, Theodore G ^f   Haddow, James E ^g   Klein, Roger D ^h   Lyman, Donald O ⁱ   Offit, Kenneth ^j   Pauker, Stephen G ^k   Piper, Margaret ^l   Richards, Carolyn Sue ^m   Strickland, Ora L ⁿ   Tunis, Sean R ^o   Veenstra, David L ^c  

^a Colorado Department of Public Health and Environment ^*  (United States)

^b Washington State Health Care Authority   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BROWN UNIVERSITY   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k TUFTS MEDICAL CENTER   (United States)

^l Blue Cross and Blue Shield Association   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o Center for Medical Technology Policy   (United States)

more..

Author keywords

BRAF; EGFR; KRAS; mCRC; metastatic colorectal cancer

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CODON; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; METASTATIC COLORECTAL CANCER; MONOTHERAPY; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SKIN TOXICITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; VALIDITY; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENETIC TESTING; GTP PHOSPHOHYDROLASES; GUIDELINES AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84880544985     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.184     Document Type: Article

References (68)

1. US Food and Drug Administration. Full prescribing information for cetuximab (Erbitux®). July 2012 revision. http://www.accessdata.fda.gov/ drugsatfda- docs/label/2012/125084s225lbl.pdf. Accessed 13 November 2012.
2. US Food and Drug Administration. Full prescribing information for panitumumab (Vectibix®). August 2012 revision. http://www.accessdata.fda. gov/drugsatfda-docs/label/2012/125147s0148lbl.pdf. Accessed 13 November 2012.
3. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
4. National Comprehensive Cancer Network
5. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
6. American Cancer Society. Cancer Facts and Figures 2010.
7. Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol 2008;65:8-20.
8. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-1261.
9. Lin JS, Webber EM, Senger CA, Holmes RS, Whitlock EP. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 2011;1: 650-662.
10. Legolvan MP, Taliano RJ, Resnick MB. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. Hum Pathol 2012;43:1157-1168.
11. Brown HM. KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer. Technol Eval Cent Asses Program 2009;23:1-20.
12. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
13. Keating GM. Spotlight on panitumumab in metastatic colorectal cancer. BioDrugs 2010;24:275-278.
14. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010;70:1059-1078.
15. Odom D, Barber B, Bennett L, et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis 2011;26:173-181.
16. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
18. Rizzo S, Bronte G, Fanale D, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010;36 Suppl 3:S56-S61.
19. Lin J, Webber B, Holmes R, Senger C, Lai S, Whitlock E. Systematic review: EGFRrelated pharmacogenetic testing (downstream to KRAS) for predicting clinical benefit to cetuximab and panitumumab in metastatic colorectal cancer. http://www.egappreviews.org (2012).
20. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011;223:219-229.
21. College of American Pathologists Technology Assessment Committee (TAC). Perspectives on Emerging Technology: KRAS Mutation Testing for Colorectal Cancer. College of American Pathologists; version 4: Northfield IL, 2009.
22. US Food and Drug Administration. Cetuximab (Erbitux) and Panitumumab (Vectibix). http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905. htm. Accessed 24 February 2011.
23. Terasawa T, Dhabreh I, Castaldi PJ, Trikalinos AT. Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia. AHRQ Technology Assessment Program 2010. http://www.cms.gov/DeterminationProcess/downloads/ id76TA.pdf. Accessed 16 February 2011.
24. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Antiepidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011;154:37-49.
25. Medical Advisory Secretariat. KRAS testing for anti-EGFR therapy in advanced colorectal cancer: an evidence-based and economic analysis. http://www. health.gov.table.
26. Medical Advisory Secretariat. KRAS testing for anti-EGFR therpy in advanced colorectal cancer: Ontario Health Technology Advisory Committee. http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/ rec-KRAS-20101213.pdf. Accessed 24 February 2011.
27. Teutsch SM, Bradley LA, Palomaki GE, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
28. Botkin JR, Teutsch SM, Kaye CI, et al.; EGAPP Working Group. Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med 2010;12:228-235.
29. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-552.
30. Fariña Sarasqueta A, Moerland E, de Bruyne H, et al. SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn 2011;13:199-205.
31. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13:64-73.
32. Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists. Acta Gastroenterol Belg 2010;73:497-503.
33. Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010;17:23-32.
34. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
35. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
36. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-2629.
37. Mancuso A, Sollami R, Recine F, Cerbone L, Macciomei MC, Leone A. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. J Clin Oncol 2010;28:e756-e758.
38. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020-1026.
39. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
40. Mariani P, Lae M, Degeorges A, et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 2010;30:4229-4235.
41. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-4219.
42. Santini D, Galluzzo S, Gaeta L, et al. Should oncologists be aware in their clinical practice of KRAS molecular analysis? J Clin Oncol 2011;29:e206-7; author reply e208.
43. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
44. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:4830-4835.
45. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
46. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
47. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009.
48. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-5930.
49. National Cancer Institute. Clinical Trials (PDQ)-phase II/III randomized study of molecular selection of chemotherapy using K-ras, BRAF mutation analysis and topoisomerase-1 expression analysis in patients with metastatic or locally advanced colorectal cancer. http://www.cancer.gov/clinicaltrials/search/view?cd rid=648235&version=healthprofessional#Outline-CDR0000648235. Accessed 24 June 2011.
50. National Cancer Institute. Clinical Trials (PDQ)-phase II study of panitumumab and irinotecan hydrochloride as third-line therapy in patients with previously treated metastatic colorectal cancer without kras mutation http://www.cancer. gov/clinicaltrials/search/view?cdrid=593012&version= healthprofessional. Accessed 24 June 2011.
51. US National Institutes of Health. ClinicalTrials.gov-Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer. http://clinicaltrials.gov/ct2/show/NCT0128064 3?term=kras&intr=genetic&rank=5. Accessed 24 June 2011.
52. US National Institutes of Health. Clinical Trials.gov-presence of circulating tumor DNA in colorectal cancer (ALGECOLS). http://clinicaltrials. gov/ct2/show/NCT01198743?term=kras&intr=genetic&rank=14. Accessed 24 June 2011.
53. National Cancer Institute. Clinical Trials (PDQ)-Study of BRAF mutations as predictors of efficacy in patients with advanced colorectal cancer treated with cetuximab. http://www.cancer.gov/clinicaltrials/search/view?cdrid= 688745&ve rsion=healthprofessional. Accessed 24 June 2011.
54. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximabrelated skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013;132:236-245.
55. Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 2012;131:438-445.
56. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-384.
57. Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011;17:6338-6346.
58. Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011;34:61-66.
59. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-1820.
60. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30:3570-3577.
61. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: A systematic review and metaanalysis. Cancer 2012;doi: 10.1002/cncr.27804.
62. Chen J, Ye Y, Sun H, Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2012;e-pub ahead of print 23 October 2012.
63. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 2012;30:3565-3567.
64. National Comprehensive Cancer Network. NCCN Guidelines Version 3.2012 Rectal Cancer 01/17/12.
65. Herman J, Messersmith W, Suh WW, et al. ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer 2010;34:201-210.
66. Agency for Healthcare Research and Quality. National Guideline Clearinghouse. Guideline Summary. ACR Appropriateness Criteria® rectal cancer-metastatic disease at presentation. http://www.guidelines.gov/content. aspx?id=23843. Accessed 24 June 2011.
67. Aubin F, Gill S, Burkes R, et al. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Curr Oncol 2011;18: e180-e184.
68. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol 2010;5:23.